Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...

French pharmaceuticals giant Sanofi has agreed to acquire privately-owned British biotech firm, Vicebio, in a deal worth up ...

Blueprint Medicines' (NASDAQ:BPMC) stock was stagnant in 2024 and is up just 2% since my rating upgrade to "strong buy" in February. Back then, my focus was on the company's lead drug, Ayvakit, to ...

Blueprint Medicines (NASDAQ:BPMC) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release. Analysts are ...

Summary. Despite solid earnings beats, Blueprint Medicines is trading down ~16% since my last article. AYVAKIT/AYVAKYT revenues have doubled for four consecutive years, with 2024 guidance pegging ...

After reporting second-quarter financial results and updating investors on the progress it's making in developing cancer therapies targeting specific genetic mutations, Blueprint Medicines (NASDAQ ...

Paris: Sanofi has announced the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...